Tumor sequencing and promoter methylation analyses demonstrated that NTHL1 does not undergo bi-allelic inactivation in breast cancers, which is supported by the fact that NTHL1-het tumors retain approximately 50% of the wildtype protein expression. This evidence concerns the gene NTHL1 and breast cancer.